Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme

被引：0
|
作者：
Anna Maria Di Giacomo
Luana Calabrò
Riccardo Danielli
Ester Fonsatti
Erica Bertocci
Isabella Pesce
Carolina Fazio
Ornella Cutaia
Diana Giannarelli
Clelia Miracco
Maurizio Biagioli
Maresa Altomonte
Michele Maio
机构：
[1] University Hospital of Siena,Division of Medical Oncology and Immunotherapy, Department of Oncology, Istituto Toscano Tumori
[2] Regina Elena National Cancer Institute,Statistical Unit
[3] University Hospital of Siena,Department of Pathology
[4] University Hospital of Siena,Department of Dermatology
来源：
Cancer Immunology, Immunotherapy | 2013年 / 62卷
关键词：
Biomarker; Expanded access programme; Ipilimumab; Long-term survival; Metastatic melanoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1021 / 1028
页数：7
相关论文
共 50 条
  • [1] Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
    Di Giacomo, Anna Maria
    Calabro, Luana
    Danielli, Riccardo
    Fonsatti, Ester
    Bertocci, Erica
    Pesce, Isabella
    Fazio, Carolina
    Cutaia, Ornella
    Giannarelli, Diana
    Miracco, Clelia
    Biagioli, Maurizio
    Altomonte, Maresa
    Maio, Michele
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (06) : 1021 - 1028
  • [2] LONG TERM SURVIVAL AND IMMUNOLOGICAL CORRELATES IN METASTATIC MELANOMA TREATED WITH IPILIMUMAB AT 10 MGS WITHIN AN EXPANDED ACCESS PROGRAM
    Di Giacomo, A. M.
    Calabro, L.
    Danielli, R.
    Pesce, I.
    Fonsatti, E.
    Bertocci, E.
    Giannarelli, D.
    Biagioli, M.
    Altomonte, M.
    Maio, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 364 - 364
  • [3] Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
    Altomonte, Maresa
    Di Giacomo, Anna Maria
    Queirolo, Paola
    Ascierto, Paolo Antonio
    Spagnolo, Francesco
    Bajetta, Emilio
    Calabro, Luana
    Danielli, Riccardo
    de Rosa, Francesco
    Maur, Michela
    Chiarion-Sileni, Vanna
    Ferrucci, Pier Francesco
    Giannarelli, Diana
    Testori, Alessandro
    Ridolfi, Ruggero
    Maio, Michele
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2013, 32
  • [4] Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
    Maresa Altomonte
    Anna Maria Di Giacomo
    Paola Queirolo
    Paolo Antonio Ascierto
    Francesco Spagnolo
    Emilio Bajetta
    Luana Calabrò
    Riccardo Danielli
    Francesco de Rosa
    Michela Maur
    Vanna Chiarion-Sileni
    Pier Francesco Ferrucci
    Diana Giannarelli
    Alessandro Testori
    Ruggero Ridolfi
    Michele Maio
    Journal of Experimental & Clinical Cancer Research, 32
  • [5] Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma
    Krajsova, Ivana
    Arenberger, Petr
    Lakomy, Radek
    Kubala, Eugen
    Brezinova, Ivana
    Poprach, Alexandr
    Stastny, Marek
    Muzik, Jan
    Melichar, Bohuslav
    ANTICANCER RESEARCH, 2015, 35 (11) : 6303 - 6310
  • [6] Long-term survival of patients with advanced melanoma who received ipilimumab administered at 10 mg/kg every 3 weeks for 4 doses (induction dosing)
    Urba, W. J.
    Weber, J. S.
    O'Day, S. J.
    Powderly, J. D.
    Yellin, M. J.
    Nichol, G.
    Hersh, E. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials
    Lebbe, Celeste
    Weber, Jeffrey S.
    Maio, Michele
    Neyns, Bart
    Harmankaya, Kaan
    Hamid, Omid
    O'Day, Steven
    Chin, Kevin M.
    McDowell, Diane Opatt
    Cykowski, Lori
    McHenry, Brent
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Long-term survival in advanced melanoma patients treated with ipilimumab at 10 mg/kg: ongoing analyses from completed Phase II trials
    Maio, M.
    Lebbe, C.
    Sileni, V. Chiarion
    Siegel, J.
    Hoos, A.
    Humphrey, R.
    O'Day, S.
    Wolchok, J.
    Weber, J.
    Harmankaya, K.
    EJC SUPPLEMENTS, 2009, 7 (02): : 578 - 578
  • [9] Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma
    Gibney, Geoffrey T.
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) : 1873 - U27
  • [10] Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports
    Wilgenhof, Sofie
    Du Four, Stephanie
    Everaert, Hendrik
    Neyns, Bart
    CANCER INVESTIGATION, 2012, 30 (10) : 712 - 720
12345